Sertraline vs Escitalopram: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Sertraline inhibits the serotonin transporter with additional weak dopamine transporter activity and sigma-1 receptor binding — broader off-target effects than escitalopram's pure serotonin selectivity. CTD documents 138 gene interactions, 23x escitalopram's 6, reflecting this wider molecular footprint. The depletion mechanism is identical: increased serotonin turnover consumes folate, disrupts melatonin synthesis, and triggers SIADH sodium wasting.
Sertraline has 44% bioavailability with a 26-hour half-life and 98.5% protein binding — the highest protein binding of any SSRI, which creates significant drug displacement interaction potential.
- ✓Broadest SSRI indication list: depression, OCD, panic disorder, PTSD, social anxiety, and PMDD
- ✓Most-prescribed antidepressant in the U.S. — extensive real-world safety data
- ✓FAERS logs 67,356 reports providing comprehensive adverse event characterization
- ✓26-hour half-life allows once-daily dosing with smooth blood levels
- ✗138 CTD gene interactions — 23x more than escitalopram — indicating broader off-target effects
- ✗98.5% protein binding creates displacement risks with warfarin, phenytoin, and other highly-bound drugs
- ✗GI side effects (nausea, diarrhea) more common than with escitalopram — may impair folate absorption further
- ✗Mild dopamine reuptake inhibition adds pharmacological complexity without clear clinical advantage for most patients
Patients needing broad anxiety spectrum coverage (OCD, PTSD, panic, social anxiety) alongside depression treatment.
Escitalopram is the most selective SSRI — it targets the serotonin transporter with virtually no off-target receptor binding. CTD documents only 6 gene interactions, making it the cleanest SSRI molecular profile by a wide margin. The same three depletions occur through serotonin pathway effects: folate consumption, melatonin disruption, and SIADH sodium wasting — but without the additional pharmacological noise of sertraline's sigma and dopamine activity.
Escitalopram achieves 80% bioavailability with a 27–32 hour half-life and only 55% protein binding — the lowest of any SSRI, dramatically reducing displacement drug interactions.
- ✓Only 6 CTD gene interactions — the cleanest SSRI profile by 23x over sertraline
- ✓55% protein binding eliminates displacement interaction risks that sertraline's 98.5% creates
- ✓80% bioavailability versus sertraline's 44% — more drug reaches the target per dose
- ✓Generally better tolerated with fewer GI side effects than sertraline
- ✗Only 2 FDA indications (depression, GAD) versus sertraline's 6
- ✗FAERS logs 80,138 reports — higher volume reflecting status as most-prescribed SSRI
- ✗QTc prolongation risk at doses above 20 mg limits dose escalation in cardiac patients
- ✗27–32 hour half-life can produce mild discontinuation symptoms during tapering
First-line SSRI for depression or GAD in patients who want the cleanest pharmacological profile, lowest protein binding, and fewest drug interactions.
Feature Comparison
| Feature | Sertraline | Escitalopram |
|---|---|---|
| Drug Class | SSRI (+ weak DRI + sigma) | SSRI (pure serotonin selectivity) |
| Nutrients Depleted | 3 — sodium, folate, melatonin | 3 — sodium, folate, melatonin |
| CTD Gene Interactions | 138 documented | 6 documented (23x fewer) |
| Protein Binding | 98.5% (highest SSRI) | 55% (lowest SSRI) |
| Bioavailability | 44% | 80% |
| Half-Life | 26 hours | 27–32 hours |
| FAERS Reports | 67,356 total | 80,138 total |
| FDA Indications | 6 — depression, OCD, PTSD, panic, social anxiety, PMDD | 2 — depression, GAD |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both deplete the same three nutrients through identical serotonin reuptake inhibition. The real comparison is pharmacological cleanliness versus indication breadth. Escitalopram's 6 CTD gene interactions versus sertraline's 138 represents the widest selectivity gap between any two SSRIs — escitalopram is a laser, sertraline is a shotgun. Escitalopram's 55% protein binding eliminates the displacement interactions that sertraline's 98.5% creates. For patients with simple depression or GAD, escitalopram is the objectively cleaner choice. For patients needing OCD, PTSD, panic disorder, or social anxiety coverage alongside depression, sertraline's six FDA indications provide evidence-based breadth that escitalopram lacks. The nutrient depletion burden is identical — the decision is entirely clinical, not nutritional.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 138 gene interactions for sertraline; 6 for escitalopram — a 23x selectivity difference
- [2]ChEMBL bioactivity database: clinical trial data for both SSRIs across depression and anxiety spectrum indications
- [3]FAERS (FDA Adverse Event Reporting System): 67,356 sertraline reports; 80,138 escitalopram reports
- [4]PharmGKB pharmacogenomics database: CYP2C19 metabolism annotations for escitalopram; CYP2B6/2C19 for sertraline
- [5]PubMed PMID 19185342 — Cipriani A et al. Comparative efficacy and acceptability of 12 new-generation antidepressants. Lancet. 2009;373(9665):746-758
Check your medications
Check Free →